Archives: Summit Talks

Beyond the Summit: The Official Recap & Live Q&A

Webinar recorded: April 3, 4:00 PM ET (New York)

Go beyond the Summit with this official live webinar! We revisit the most powerful insights, standout moments, and key takeaways from this year’s expert interviews—whether you missed them or just want a deeper dive. Plus, event hosts Carl & Elizabeth will answer your questions live!

Here’s what you’ll gain:

• ✅ The biggest breakthroughs from 2025 expert interviews—perfect for catching up or refreshing your memory
• ✅ Practical strategies & expert-approved tips you can start using right away
• ✅ Additional tools & resources to support your migraine management
• ✅ Live Q&A with Carl & Elizabeth—ask your burning questions directly!
• ✅ Connect with fellow attendees in the live chat and share your experiences

Why Watch

This recorded session is your chance to solidify what you’ve learned, revisit game-changing insights, and get real-time answers. It’s also a great overview of the event if you missed out.

Quick Tip

Use the video chapters to jump to the sections you’re most interested in.

---

Note: Unlike the expert interviews from the Summit, this webinar recording recording uses automated closed captions which have not been checked for their accuracy.

Interview Notes

• Prof. Simona Sacco
• Cephalalgia
• Cephalalgia Reports
• Article: “International Headache Society global practice recommendations for the acute pharmacological treatment of migraine”
• Article: “International Headache Society global practice recommendations for preventive pharmacological treatment of migraine”

Treatments Mentioned

• Acetaminophen/Paracetamol
• Acetylsalicylic acid/Aspirin
• Amitriptyline
• Analgesics
• Antiemetics/Anti-nausea medications
• Antithrombotics
• CGRP small-molecule receptor antagonists (gepants)
• Diclofenac (Cambia)
• Dihydroergotamine (DHE)
• Dopamine antagonist
• Ergotamine
• Frovatriptan
• Hormonal contraceptives
• Lasmiditan (Reyvow)
• Magnesium
• Metoclopramide
• Migranal
• Naproxen
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Neuromodulation devices
• Rizatriptan
• Sumatriptan
• Sumatriptan and naproxen sodium (Treximet)
• Supplements
• Triptans
• Zolmitriptan

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

Interview Notes

• Research at Mayo Clinic
• Mayo Clinic Rochester
• Chia-Chun Chiang, MD
• American Migraine Foundation
• American Headache Society
• Book: Handbook of Clinical Neurology: Chapter 27
• Study: “Migraine with visual aura and the risk of stroke – a narrative review”
• Study: “Structural and functional brain changes in migraine”
• Study: “White matter hyperintensity in different migraine subtypes”
• Study: “Association of migraine and ischemic heart disease: A review”
• Study: “Association of migraine with patent foramen ovale closure: A systematic review and meta-analysis”
• Study: “Neurovascular contributions to migraine: Moving beyond vasodilation”

Treatments Mentioned

• Estrogen-containing contraceptives
• Exercise
• Diet
• Monitor vascular risk factors (e.g., blood pressure, blood sugar, and cholesterol)
• Progesterone-only contraceptives
• Quit smoking

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

Interview Notes

• Robert Bonakdar, MD
• Environmental Working Group (EWG)
• EWG – PFAS Chemicals
• EWG – Skin Deep
• EWG – Clean Fifteen
• EWG – Dirty Dozen
• Heavy metal blood test
• Vibrant America
• Genova Diagnostics
• UC San Diego Division of Medical Toxicology 
• MigraWell
• The Well Informed Podcast
• Toxic-Free Future
• Book: Non-Toxic: Guide to Living Healthy in a Chemical World
• Apps: EWG’s Healthy Living
• Website: Seafood Watch

Treatments Mentioned

• Aerobic exercise
• Antioxidants
• Coenzyme Q10 (CoQ10)
• Cruciferous vegetables
• High-fiber diet
• Hydration
• Iron
• Lifestyle modifications
• Magnesium
• Riboflavin (vitamin B2)
• Sweating
• Vitamin C
• Ventilation
• Zinc

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

Interview Notes

• • Amaal J. Starling, MD
  • American Headache Society (AHS)
  • Article: “Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update”
  • Article: “AHS Launches Position Statement About Integrating New Migraine Treatments into Clinical Practice”
  • Article: “Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY (fremanezumab) SPACE Trial for Prevention of Episodic Migraine”
  • Study: “Effect of ubrogepant on patient-reported outcomes when administered during the migraine prodrome”
  • Study: “Constipation as a possible predictor of poor treatment response in chronic migraine: A retrospective study of anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies and the impact of switching”
  • Review Article: “Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review”
  • Study: “Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: A multicenter real-world case-control study”
  • Study: “A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention”

Treatments Mentioned

• Amitriptyline
• Anticonvulsants
• Antidepressants
• Atogepant (Qulipta/Aquipta)
• Beta-blockers
• CGRP inhibitors
• CGRP monoclonal antibodies (mAbs)
• CGRP small-molecule receptor antagonists (gepants)
• Eptinezumab (Vyepti)
• Erenumab (Aimovig)
• Fremanezumab (Ajovy)
• Galcanezumab (Emgality)
• Rimegepant (Nurtec ODT/Vydura)
• Sumatriptan (Imitrex)
• Topiramate (Topamax)
• Triptans
• Ubrogepant (Ubrelvy)

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

Interview Notes

• Paula Dumas
• Migraine Again
• World Health Education Foundation
• Migraine at Work
• LinkedIn: Paula K. Dumas
• Facebook: Paula K. Dumas
• Instagram: @pauladumasauthor

Treatments Mentioned

• Art therapy
• Biofeedback
• Diet
• Exercise
• Inpatient hospitalization
• Massage therapy
• Sleep management
• Staying up to date on the latest migraine research
• Support groups

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

Interview Notes

• Wade Cooper, DO
• Immunoglobulins Blood Test
• GI360
• Study: “Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine”
• Study: “Making migraine easier to stomach: The role of the gut−brain−immune axis in headache disorders”
• Study: “A causal effects of gut microbiota in the development of migraine”
• Study: “Association of blast exposure in military breaching with intestinal permeability blood biomarkers associated with leaky gut”

Treatments Mentioned

• Amitriptyline
• CGRP-targeted medications (CGRP inhibitors)
• Fiber
• Dairy-free diet
• Gluten-free diet
• Nortriptyline
• Omega-3s
• Probiotics
• Sumatriptan
• Tricyclic antidepressants (TCAs)

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

Interview Notes

• Richard B. Lipton, MD
• Montefiore Headache Centre
• International Classification of Headache Disorders Third Edition (ICHD-3) 
• Study: “Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: Results of the American Migraine Prevalence and Prevention (AMPP) study”
• Article: “Understanding Research: What is the American Migraine Prevalence and Prevention (AMPP) Study and What We Have Learned From It?”
• Study: “Risk factors for migraine disease progression: a narrative review for a patient-centered approach”
• Study: “Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO study”
• Study: “Are we closer to achieving precision medicine for migraine treatment? A narrative review”
• Study: “Candesartan in migraine prevention: results from a retrospective real-world study”

Treatments Mentioned

• Angiotensin II receptor blockers (ARBs)
• Atogepant (Qulipta/Aquipta)
• Barbiturates
• Caffeine
• Candesartan
• Cognitive behavioral therapy (CBT)
• CGRP monoclonal antibodies (mAbs)
• Fiorinal
• Fioricet
• CGRP small-molecule receptor antagonists (gepants)
• Mindfulness
• Narcotics
• Neuromodulation devices
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• OnabotulinumtoxinA (Botox)
• Opioids
• Rimegepant (Nurtec ODT/Vydura)
• Topiramate (Topamax)
• Triptans
• Ubrogepant (Ubrelvy)
• Zavegepant (Zavzpret)

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

Interview Notes

• Richard B. Lipton, MD
• Montefiore Headache Centre
• International Classification of Headache Disorders Third Edition (ICHD-3) 
• Rami Burstein
• Study: “Reversion from chronic migraine to episodic migraine in patients treated with fremanezumab: Post hoc analysis from HALO CM study”
• Study: “Brain changes in responders vs. non-responders in chronic migraine: Markers of disease reversal”

Treatments Mentioned

• Atogepant (Qulipta/Aquipta)
• Caffeine
• CEFALY
• CGRP monoclonal antibodies (mAbs)
• Cognitive behavioral therapy (CBT)
• Cognitive behavioral therapy for insomnia (CBT-I)
• Divalproex sodium
• Exercise
• Fremanezumab (Ajovy)
• CGRP small-molecule receptor antagonists (gepants)
• Indomethacin
• Ketamine
• Neuromodulation devices
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Nutritional counseling
• OnabotulinumtoxinA (Botox)
• Psychedelics
• Rimegepant (Nurtec ODT/Vydura)
• Transcutaneous electrical nerve stimulation (TENS)
• Topiramate (Topamax)
• Transcranial magnetic stimulation (TMS)
• Triptans
• Ubrogepant (Ubrelvy)
• Vagus nerve stimulation
• Zavegepant (Zavzpret)

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

Interview Notes

• Integrative Headache Medicine of New York
• Epworth Sleepiness Scale
• STOP-Bang Questionnaire 
• Instagram: @laurennatbonymd
• LinkedIn: Lauren R. Natbony
• X: @LaurenNatbonyMD
• Facebook: Dr. Lauren R. Natbony

Treatments Mentioned

• Amitriptyline
• Benadryl
• Beta-blockers
• Cognitive behavioral therapy for insomnia (CBT-I)
• Hormone replacement therapy (HRT)
• Iron
• Light therapy box
• Limiting screen time
• Magnesium
• Melatonin
• Nighttime relaxing rituals
• Selective serotonin and norepinephrine reuptake inhibitor (SNRIs)
• Sleep diary
• Supportive pillow

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

Interview Notes

• Vincent T. Martin, MD
• The International Classification of Headache Disorders (ICHD-3)
• Study: “Sinus headache: A clinical conundrum”
• Study: “The sinus, allergy and migraine study (SAMS)”
• Study: “Chronic rhinitis and its association with headache frequency and disability in persons with migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study”
• Study: “Lightning and its association with the frequency of headache in migraineurs: An observational cohort study”
• Study: “Allergy and immunotherapy: Are they related to migraine headache?”
• Abstracts: 2024 American Headache Society Conference
• Article: “Is There a Link Between Hotter Temps and Increased Migraine Headaches?”
• Poster: “Treatment with fremanezumab attenuates the association between weather and headache in participants with episodic migraine: A post-hoc analysis of the HALO-EM study”

Treatments Mentioned

• Antihistamines
• Fluticasone (Flonase)
• Montelukast sodium (Singulair)
• Pressure-filtering earplugs (WeatherX)
• Tracking barometric pressure

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.